CoRegen’s pipeline targets aggressive cancers using Treg cell engineering and molecular regulators, with applications in regenerative healing and precision medicine.

Engineered SRC-3 KO Treg cells have been stress tested in various conditions:

28 day vein to vein process, with goal to reduce to 14 day

As trailblazers in Molecular Endocrinology, CoRegen's scientists are renowned experts in the biology of the SRC gene family, with over 300 publications in prestigious, peer-reviewed journals.

CoRegen is a biotechnology company led by experts in life sciences, focusing on scientific innovation and patient impact.

CoRegen combines expertise in molecular endocrinology, regenerative medicine, immunotherapy, and pharmaceutical development to advance cancer treatment and precision medicine.

The O’Malley lab pioneered research on steroid receptor coactivators (SRCs), identifying them as master regulators of genetic function and transforming disease treatment.

CoRegen develops outpatient therapies to eradicate cancer without toxicity by leveraging immune system discoveries.

CoRegen, Inc. secures FDA clearance to begin Phase 1/2a clinical trials for its cell therapy candidate **CRG-150**, targeting multiple solid tumor types. The therapy represents a novel approach in oncology, leveraging advanced cell-based treatments. Clinical evaluation will assess safety and preliminary efficacy in patients with diverse solid tumors.

Jul 2026GlobeNewswireNews article

CoRegen Inc. releases preclinical data showing SRC-3 engineered regulatory T cells (Tregs) as a potential immunotherapy approach for treating solid tumors. The findings highlight a differentiated cell therapy platform designed to modulate immune responses in cancer patients. The company’s research focuses on enhancing Treg functionality to improve tumor targeting.

Mar 2026GlobeNewswireNews article

CoRegen, Inc. appoints **Sonja Nelson** as **Chief Financial Officer (CFO)** and **Peter Gelinas** as **Chief Technical Officer (CTO)** to bolster its leadership. The hires expand the company’s executive team amid growth initiatives in regenerative medicine. Nelson brings financial expertise, while Gelinas contributes technical leadership to advance CoRegen’s research and development pipeline.

Sep 2025GlobeNewswireNews article

CoRegen, Inc. names Sonal Gupta, M.D., Ph.D., a biotech executive with extensive experience, as its new Chief Medical Officer. Gupta brings a background in medical leadership and drug development to the regenerative medicine company. The appointment strengthens CoRegen’s clinical and research capabilities.

Jul 2025GlobeNewswireNews article